Tag: RET Inhibitors

Home / RET Inhibitors

Categories

Selpercatinib is approved by the USFDA for medullary thyroid cancer with a RET mutation

 On September 27, 2024, the Food and Drug Administration conferred traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients aged 2 years and older diagn...
ret-inhibitors

medullary thyroid cancer treatment

Medullary Thyroid Cancer Treatment Medullary thyroid cancer (MTC) is an aggressive but rare type of thyroid cancer that develops from the parafollicular C cells of the thyroid gland. In contrast to o...
ret-inhibitors

Scan the code